BiotechTube

Bilastine + Desloratadine + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Seasonal Allergic Rhinitis

Conditions

Seasonal Allergic Rhinitis

Trial Timeline

Jun 1, 2011 → May 1, 2014

NCT ID
NCT01400828

About Bilastine + Desloratadine + Placebo

Bilastine + Desloratadine + Placebo is a phase 3 stage product being developed by Yuhan for Seasonal Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01400828. Target conditions include Seasonal Allergic Rhinitis.

What happened to similar drugs?

20 of 20 similar drugs in Seasonal Allergic Rhinitis were approved

Approved (20) Terminated (0) Active (0)
✅montelukastMerckApproved
✅Cell-derived influenza vaccine + Egg-derived influenza vaccineNovartisApproved
✅KetotifenNovartisApproved
✅Fexofenadine HClSanofiApproved
✅Placebo nasal spray + Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ) + Placebo nasal spray + Claritin® SyrupSanofiApproved
✅fexofenadine HClSanofiApproved
✅levocetirizine dihydrochlorideUCBApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01400828Phase 3Completed

Competing Products

20 competing products in Seasonal Allergic Rhinitis

See all competitors
ProductCompanyStageHype Score
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1010ModernaPhase 3
0
mRNA-1030ModernaPhase 2
0
mRNA-1010ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
ASP4070 + PlaceboAstellas PharmaPhase 2
35
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
35
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
35
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
80 mcg Ciclesonide + 160 mcg Ciclesonide + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + PlaceboSumitomo PharmaPhase 3
40
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)Glenmark PharmaceuticalsPhase 2
35
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal sprayGlenmark PharmaceuticalsPhase 2
35
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placeboJohnson & JohnsonPhase 1
29
Ciclesonide + PlaceboAstraZenecaPhase 3
40
Ciclesonide + PlaceboAstraZenecaPhase 3
40
Ciclesonide HFA + Ciclesonide HFA + Ciclesonide HFA + PlaceboAstraZenecaPhase 2
35